Download SANGLY P. SRINIVAS

SANGLY P. SRINIVAS
Associate Professor
School of Optometry, Indiana University,
Bloomington, IN, USA
Phone: 812-855-0132 Fax: 812-855-7045
Email: [email protected]
Education
PhD in Chemical Engineering, Drexel University, Philadelphia
MS in Chemical Engineering, I. I. T., Madras, India
BS in Chemical Engineering, K.R.E College, Mangalore, India
Research Interest
- Cell volume regulation in corneal endothelial cells.
- Regulation of aqueous humor outflow by trabecular meshwork cells.
- Mechanotransduction in corneal epithelial cells.
Honors
October 1995
- Present
August 1999August 2000
1999- 2000
Summer, 2001
2001
2002
National Institute of Health: Volume Regulation in Corneal
Endothelium
American Optometric Foundation for Vistakon Research Grants
Contact Lens Induced Changes in Corneal Epithelial
Permeability: Role of Inflammatory Mediators.
Classroom Technology Award Web Technology for Teaching
Pharmacology and Systemic Disease (University of California,
Berkeley)
Intercampus Award (with Prof. Gallagher of IUPUI, Department of
Biophysics as co- investigator) Corneal endothelial permeability:
Regulation by myosin light chain kinase
Beatrice and Irwin Borish Award
American Optometric Foundation Teaching & Learning
Invited Speaker
2001
August 2002September
2003
Technologies Lab, Indiana University
Contact Lens-Induced Mechanotransduction in the Ocular
Surface Epithelia Submitted to American Optometric Foundation
(Vistakon Grant), July 30th, 2001.
Measurement of Rapid Changes in Cell Volume for High-Throughput
Screening of Ion Channels Society for Biomolecular Screening, Small
Grants Program.
Invitations and Guest Professorships
1992
1992
1997
1997
1998
1999
2000
2000
2001
2001
2001
2002
2002
2002
Applications of fluorescein in ocular drug delivery Dept. of Ophthalmology,
University of Nebraska, Omaha, Nebraska
Ocular pharmacokinetics of fluorescein Alza, Palo Alto, California
Receptor mediated regulatory volume control in corneal endothelium School
of Optometry, University of California, Berkeley
Cell volume regulation in corneal endothelium Department of
Ophthalmology, University of Michigan, Ann Arbor, MI
Biomedical engineering challenges in the anterior segment of the human
Eye Chemical Engineering, Drexel University, Philadelphia, PA
How do cells regulate their volume? Relevance to endothelial function
School of Optometry, Indiana University, Bloomington, IN
Changes in corneal endothelial cell volume induced by activation of
purinergic Receptors Katholieke Universiteit, Laboratory of Physiology,
LEUVEN, Belgium
An introduction to mechanotransduction on the ocular surface Indiana
Optometry Association, Fall Seminar
Topical drug delivery: Microscopic Aspects School of Optometry, Indiana
University, Bloomington, IN
Mechanotranduction in the ocular surface epithelia. Ciba Vision, Atlanta,
Georgia
Molecular components of mechanotransduction: Implications to ocular
surface homeostasis by BLISS (Blink- Induced Shear Stress) International
Society of Contact Lens Research, Sun Valley, Idaho
Primary Open Angle Glaucoma- Yet another Conformational Disease?
School of Optometry, Indiana University, Bloomington, IN
Extra/Intracellular Stress Response: Implications for the Pathophysiology of
the Anterior Segment of the Human Eye. Biomedical Colloquia Medical
Sciences, Indiana University, Bloomington, IN
Frequency-Domain Fluorometry for pO2 Sensing Organized by Ocumetrics
Inc. during Association for Research in Vision and Ophthalmology
Invited Speaker
Abstract
Ocular Drug Delivery: Is There A Niche for Nanotechnology?
S.P. Srinivas1, Uracha Ruktanonchai2, and Udaya Kompella3
1
2
Indiana University, School of Optometry, Bloomington, IN.
National Nanotechnology Center, National Science and Technology Development Agency (NSTDA), Pathumthani,
Thailand.
3
University of Colorado, Denver, CO.
The major ocular diseases that require chronic pharmacological intervention
include glaucoma, age related macular degeneration, uveitis, dry eye, and diabetic
retinopathy. Many novel agents being developed or already in the market for these
disorders require special considerations for their delivery to the intended target sites.
Several anatomical barriers in combination with blood flow and dynamics of intra- and
extraocular fluids pose unique challenges for facile drug delivery meeting the standards
of acceptable bioavailability and pharmacokinetic characteristics. Although there are no
nanoparticles in use currently for clinical applications in the eye, several recent
investigations seem to suggest that a wide spectrum of micro- and nanoparticles hold
promising niche for ocular drug delivery. This presentation will discuss some of the
recent applications of nanoparticles in delivering drugs to target tissues in the anterior
and posterior segments of the eye in addition to a critical review of challenges facing
ocular drug delivery.
Invited Speaker